BridgeBio Pharma Inc (NASDAQ:BBIO) currently has a daily average trading volume of 2.01M but it saw 2721040 shares traded in last market. With a market cap of 4.91B USD, the company’s current market price of $25.98 came falling about -6.61 while comparing to the previous closing price of $27.82. In past 52 weeks, the stock remained buoying in the range of price level as high as $44.32 and as low as $21.62. In the recent trading on the day, stock has struck highest price mark of $25.51 while lowest mark touched by it was $28.15.
Taking a look at 20-day trading activity of BridgeBio Pharma Inc (BBIO) gives us an average price of $26.89, while its current price level is -41.38% below from 52-week high level whereas it is 20.17% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $25.67 while that of 200 days or SMA-200 reads an average of $26.65. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.42% during that period while stretching the period over a month that increases to 5.62%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 46.15 which implies that the stock is in neutral territory.
Piper Sandler also issued its recommendations for the stock as it initiated the price target for the stock is $46.
Over the week, BBIO’s stock price is moving -10.35% down while it is 16.24% when we observe its performance for the past one month. Year-to-date it is -35.65% down and over the past year, the stock is showing a downside performance of -32.41%.
The company is expected to be releasing its next quarterly report in January, for which analysts forecasted an EPS of -0.82 while estimate for next year EPS is -2.03. In next quarter, company is expected to be making quarterly sales of $48.91M as analysts are expecting the sales for current fiscal year at $307.13M and seeing the company making $186.82M in sales next year. Moreover, analysts are in estimates of $36.82M for current-quarter revenue.
Currently, BridgeBio Pharma Inc’s total number of outstanding shares is 188.99M. Company’s return on investment (ROI) stands at -88.62%. Stock’s beta reads 1.06. Stock has a price to sale or P/S ratio amounts to 22.55. Its return on asset (ROA) is -66.49% on average.
